ES2135472T3 - Antagonistas de angiotensina ii contra trastornos asociados con la velocidad de conduccion neuronal deteriorada, especialmente la neuropatia diabetica. - Google Patents

Antagonistas de angiotensina ii contra trastornos asociados con la velocidad de conduccion neuronal deteriorada, especialmente la neuropatia diabetica.

Info

Publication number
ES2135472T3
ES2135472T3 ES93909041T ES93909041T ES2135472T3 ES 2135472 T3 ES2135472 T3 ES 2135472T3 ES 93909041 T ES93909041 T ES 93909041T ES 93909041 T ES93909041 T ES 93909041T ES 2135472 T3 ES2135472 T3 ES 2135472T3
Authority
ES
Spain
Prior art keywords
angiotensin
diabetic neuropathy
neuronal
deteriorated
driving speed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93909041T
Other languages
English (en)
Inventor
Frank Carey
Alexander Anthony Oldham
Norman Eugene Cameron
Mary Anne Cotter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929208116A external-priority patent/GB9208116D0/en
Priority claimed from GB929211289A external-priority patent/GB9211289D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of ES2135472T3 publication Critical patent/ES2135472T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

ESTA INVENCION DESCRIBE EL EMPLEO DE ANTAGONISTAS DE ANGIOTENSIN II EN TRATAR O PREVENIR EL DESARROLLO DE LAS CONDICIONES DE ENFERMEDADES ASOCIADAS CON LA VELOCIDAD DE CONDUCCION NEURONAL DAÑINA, TAL COMO NEUROPATIA DIABETICA, COMO TAMBIEN SU APLICACION EN LA FABRICACION DE UN MEDICAMENTO PARA USO EN TAL TRATAMIENTO. LA INVENCION TAMBIEN CONCIERNE A LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN UN ANTAGONISTA DE ANGIOTENSIN II JUNTO CON UNO O MAS OTROS AGENTES CONOCIDOS PARA SER DE VALOR EN TRATAR O PREVENIR EL DESARROLLO DE LAS CONDICIONES DE ENFERMEDAD ASOCIADAS CON LA VELOCIDAD DE CONDUCCION NEURONAL DAÑINA
ES93909041T 1992-04-13 1993-04-07 Antagonistas de angiotensina ii contra trastornos asociados con la velocidad de conduccion neuronal deteriorada, especialmente la neuropatia diabetica. Expired - Lifetime ES2135472T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929208116A GB9208116D0 (en) 1992-04-13 1992-04-13 Therapeutic agents
GB929211289A GB9211289D0 (en) 1992-05-28 1992-05-28 Heterocyclic therapeutic agents

Publications (1)

Publication Number Publication Date
ES2135472T3 true ES2135472T3 (es) 1999-11-01

Family

ID=26300705

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93909041T Expired - Lifetime ES2135472T3 (es) 1992-04-13 1993-04-07 Antagonistas de angiotensina ii contra trastornos asociados con la velocidad de conduccion neuronal deteriorada, especialmente la neuropatia diabetica.

Country Status (14)

Country Link
EP (2) EP0636027B1 (es)
JP (1) JPH07505646A (es)
KR (1) KR100292396B1 (es)
AT (1) ATE181830T1 (es)
AU (1) AU675935B2 (es)
CA (1) CA2132544C (es)
DE (1) DE69325574T2 (es)
DK (1) DK0636027T3 (es)
ES (1) ES2135472T3 (es)
GR (1) GR3031261T3 (es)
HU (1) HUT71331A (es)
NO (1) NO313935B1 (es)
NZ (1) NZ251741A (es)
WO (1) WO1993020816A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11513395A (ja) * 1995-10-06 1999-11-16 ノバルティス・アクチエンゲゼルシャフト 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト
ATE230263T1 (de) 1996-02-29 2003-01-15 Novartis Erfind Verwalt Gmbh At1 rezeptor antagonist zur anregung von apoptosis
NZ330774A (en) * 1996-04-05 1999-06-29 Takeda Chemical Industries Ltd Pharmaceutical composition having angiotensin ii antagonistic activity or salt thereof with an insulin-sensitivity increasing compound and postprandial hyperglycemia in diabetes mellitus and antagonistic activity and increased insulin-sensitivity
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
NZ511938A (en) 1998-12-23 2004-02-27 Novartis Ag Use of AT-1 receptor antagonist or treating diseases associated with an increase of AT-1 receptor
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
NZ555334A (en) 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
JP5230595B2 (ja) 2006-03-20 2013-07-10 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 炎症性疼痛の治療または予防の方法
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
ES2560327T3 (es) * 2010-01-19 2016-02-18 Novartis Ag Métodos y composiciones para una velocidad de conducción nerviosa mejorada
NZ759782A (en) 2017-07-07 2023-06-30 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
EP3996709A1 (en) 2019-07-09 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Telmisartan for the treatment of hypertension in dogs
CN121175053A (zh) 2023-05-24 2025-12-19 勃林格殷格翰动物保健有限公司 包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防
TW202541793A (zh) 2023-12-15 2025-11-01 德商百靈佳殷格翰維美迪加股份有限公司 用於預防貓之全身性疾病之血管緊張素ii受體拮抗劑

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE117294T1 (de) * 1989-08-11 1995-02-15 Ici Plc Chinolin-derivate, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel.
GB8927277D0 (en) * 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
US5049565A (en) * 1990-12-07 1991-09-17 Merck & Co., Inc. Microbial transformation process for preparing anti-hypertensive products
GB9027210D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
AU1625192A (en) * 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
DK0528762T3 (da) * 1991-08-15 1997-08-25 Ciba Geigy Ag N-acyl-N-heterocyclyl- eller naphthylalkyl-aminosyrer som angiotensin II antagonister

Also Published As

Publication number Publication date
JPH07505646A (ja) 1995-06-22
DE69325574T2 (de) 2000-03-16
NZ251741A (en) 1997-06-24
NO943846L (no) 1994-10-12
HU9402932D0 (en) 1995-02-28
EP0636027B1 (en) 1999-07-07
GR3031261T3 (en) 1999-12-31
ATE181830T1 (de) 1999-07-15
EP0636027A1 (en) 1995-02-01
AU3958993A (en) 1993-11-18
CA2132544A1 (en) 1993-10-28
DE69325574D1 (de) 1999-08-12
WO1993020816A1 (en) 1993-10-28
CA2132544C (en) 2005-10-18
EP0872235A1 (en) 1998-10-21
DK0636027T3 (da) 2000-01-31
HUT71331A (en) 1995-11-28
KR100292396B1 (es) 2001-09-17
AU675935B2 (en) 1997-02-27
NO313935B1 (no) 2002-12-30
NO943846D0 (no) 1994-10-12

Similar Documents

Publication Publication Date Title
NO943846D0 (no) Angiotensin II antagonister mot forstyrrelser knyttet til svekket nerveledningshastighet, særlig diabetisk nevropati
CO4910133A1 (es) Antagonistas de 5-h[1f]
CA2312528A1 (fr) Composition cosmetique raffermissante comprenant au moins un hydroxystilbene en association avec de l'acide ascorbique
BR9806747A (pt) Sistema terapêutico transdérmico.
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
ATE206432T1 (de) A3 -adenosin -rezeptor agonisten
FI882791A7 (fi) Aineita, jotka parantavat määrättyjen 1,4-dihydropyridiinijohdannaisten siirtymistä ihon läpi.
CA2245125A1 (fr) Utilisation d'un extrait d'au moins un vegetal de la famille des rosacees
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
FI902825A7 (fi) Voiteluaine- ja funktionaaliset nestekoostumukset, joilla on parempi e mulsioiden hajaantuvuus
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
ES2058346T3 (es) Compuestos piperidinilicos 1,4-disustituidos.
DK0615751T3 (da) Anvendelse af tachykininantagonister til behandling af emesis
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
DE3870409D1 (de) Alkoholfreie fluessige make up-zusammensetzung.
ES2080736T3 (es) Uso de 2,3,4,5-tetrahidro-1h-3-benzazepinas en el tratamiento de trastornos neurologicos.
TNSN97173A1 (fr) Analogues peptidiques de la lh-rh, leurs utilisations et les compositions pharmaceutiques en contenant.
ATE195055T1 (de) Insektizide zusammensetzung die diatomeenerde und siliziumdioxid enthalten
EP0147282A3 (fr) Compositions cosmétiques anti-surcharges graisseuses et application sur le corps humain par ionophorèse
ATE219679T1 (de) Zusammensetzung zur vorbeugung und behandlung von urogenitalen störungen, die wismut und eine oder mehrere antimikrobielle mitteln enthalten
ATE373475T1 (de) Carbamate von 2-heterozyklischen 1,2-ethandiolen
PT865284E (pt) Composicoes contendo bismuto e um ou mais anti-microbioticos para a prevencao e tratamento de perturbacoes gastrointestinais
TR199801021T2 (xx) Mide-ba��rsak bozukluklar�n�n �nlenmesi ve tedavisi i�in bizmut i�eren bile�imler.
FR2786099B1 (fr) Nouvelle application therapeutique de la 1,6-dimethyl-8beta- hydroxymethyl-10alpha-methoxyergoline
ES555466A0 (es) Mejoras introducidas en el objeto de la patente de invencion 516.212 por perfeccionamientos introducidos en atomizadores agricolas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 636027

Country of ref document: ES